ARCHIVES

Study: Angiopoietin-2 Levels May Predict Lenvatinib Response

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

Letter: Biostatistics Directors Invited To Share Concerns

June 7, 1996

Also in this 12-page issue: NCI gives Doroshow and Fine “lead role” in clinical trials system review.

November 14, 2003

Groups Offer Revisions to Kennedy-Hutchison Bill

May 15, 2009

Copyright Violation Of Cancer Letter – Results In Payment

July 19, 1991

National Toxicology Program: Saccharin No Longer Listed as Carcinogen in NTP Report

May 19, 2000

Rituximab After CVP Improves Progression-Free Survival

March 27, 2009